Physician profile
Billy R Gilbert
NPI 1164685731
$1,335.46
in general payments reported to CMS, 2019-2025
17 companies · $84.04 in 2025
The $84.04 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $74.86 · 2021: $109 · 2022: $330 · 2023: $161 · 2024: $194 · 2025: $84.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $404 · Education: $35.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $403.80 |
| Education | $35.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $533.26 | 2019-2024 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $162.65 | 2021-2025 | Farxiga, Lokelma |
| Nxstage Medical, INC. | $118.84 | 2022 | |
| Fresenius USA Marketing, INC. | $84.31 | 2021-2024 | Velphoro, Korsuva |
| Akebia Therapeutics INC | $78.77 | 2020-2024 | Auryxia, Vafseo |
| Otsuka America Pharmaceutical, INC. | $59.59 | 2021-2022 | |
| Horizon Therapeutics Plc | $48.08 | 2022 | |
| Ardelyx, INC. | $43.84 | 2024 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $43.26 | 2022 | |
| Novo Nordisk INC | $32.27 | 2024 | Ozempic |
| Alnylam Pharmaceuticals INC. | $27.53 | 2021 | |
| Novartis Pharmaceuticals Corporation | $27.51 | 2025 | |
| Amgen INC. | $19.76 | 2025 | Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.92 | 2024 | Jardiance |
| Aurinia Pharma U.S., INC. | $17.12 | 2023 | Lupkynis |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $16.43 | 2023 | Tarpeyo |
| Travere Therapeutics, INC. | $3.32 | 2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Billy Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.